EconPapers    
Economics at your fingertips  
 

Discovery of a potent HMG-CoA reductase degrader that eliminates statin-induced reductase accumulation and lowers cholesterol

Shi-You Jiang, Hui Li, Jing-Jie Tang, Jie Wang, Jie Luo, Bing Liu, Jin-Kai Wang, Xiong-Jie Shi, Hai-Wei Cui, Jie Tang, Fan Yang, Wei Qi, Wen-Wei Qiu () and Bao-Liang Song ()
Additional contact information
Shi-You Jiang: Wuhan University
Hui Li: East China Normal University
Jing-Jie Tang: Chinese Academy of Sciences
Jie Wang: East China Normal University
Jie Luo: Wuhan University
Bing Liu: East China Normal University
Jin-Kai Wang: Wuhan University
Xiong-Jie Shi: Wuhan University
Hai-Wei Cui: East China Normal University
Jie Tang: East China Normal University
Fan Yang: East China Normal University
Wei Qi: ShanghaiTech University
Wen-Wei Qiu: East China Normal University
Bao-Liang Song: Wuhan University

Nature Communications, 2018, vol. 9, issue 1, 1-13

Abstract: Abstract Statins are inhibitors of HMG-CoA reductase, the rate-limiting enzyme of cholesterol biosynthesis, and have been clinically used to treat cardiovascular disease. However, a paradoxical increase of reductase protein following statin treatment may attenuate the effect and increase the side effects. Here we present a previously unexplored strategy to alleviate statin-induced reductase accumulation by inducing its degradation. Inspired by the observations that cholesterol intermediates trigger reductase degradation, we identify a potent degrader, namely Cmpd 81, through structure–activity relationship analysis of sterol analogs. Cmpd 81 stimulates ubiquitination and degradation of reductase in an Insig-dependent manner, thus dramatically reducing protein accumulation induced by various statins. Cmpd 81 can act alone or synergistically with statin to lower cholesterol and reduce atherosclerotic plaques in mice. Collectively, our work suggests that inducing reductase degradation by Cmpd 81 or similar chemicals alone or in combination with statin therapy can be a promising strategy for treating cardiovascular disease.

Date: 2018
References: Add references at CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
https://www.nature.com/articles/s41467-018-07590-3 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:9:y:2018:i:1:d:10.1038_s41467-018-07590-3

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-018-07590-3

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

 
Page updated 2025-03-19
Handle: RePEc:nat:natcom:v:9:y:2018:i:1:d:10.1038_s41467-018-07590-3